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As far as secondary stroke prevention by 
PFO closure is concerned, it has to be kept 
in mind that the annual risk of stroke due to 
PFO is low compared with other stroke mech-
anisms. Therefore, PFO should not be consid-
ered a cause of stroke until a thorough work-
up has excluded alternative mechanisms. Such 
workup should be postponed in patients with 
active COVID-19.
In summary, we argue against PFO screening 
in patients with COVID-19. In our opinion, the 
“less is more” approach is fully justified both on 
clinical grounds and to protect medical person-
nel from the unnecessary risk of SARS -CoV-2 
infection.
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Authors’ reply We would like to thank Ra-
jendram et al1 for their interest in our coronavi-
rus disease 2019 (COVID-19) echocardiograph-
ic guidelines in the context of screening for pat-
ent foramen ovale (PFO) in patients with COV-
ID-19.2 However, we disagree with the hypothe-
sis that screening for PFO with bubble -contrast 
echocardiography and percutaneous closure of 
PFO should be continued during the COVID-19 
pandemic.1
Rajendram et al1 stated that, in selected high -
-risk patients with COVID-19, percutaneous clo-
sure of PFO could markedly improve hypoxia, re-
duce the need for invasive ventilation, and help 
to prevent paradoxical embolism. In our opin-
ion, whereas the right -to -left shunt through 
PFO may, to some extent, contribute to hypox-
ia, it is certainly not the actual cause of the pa-
tient’s grave clinical status in acute respirato-
ry distress syndrome (ARDS) induced by se-
vere acute respiratory syndrome coronavirus 2 
(SARS -CoV-2) infection. Evidence concerning 
the prognostic significance of the presence of 
PFO in ARDS is equivocal.3 A right -to -left shunt 
may be even protective against right ventricular 
dysfunction in acute ARDS -associated cor pul-
monale.4 Its closure may therefore potential-
ly lead to deterioration of the right ventricular 
function. Overall, there is no unequivocal evi-
dence coming from well -designed clinical trials, 
which would demonstrate that PFO closure fa-
vorably affects prognosis in patients with severe 
hypoxia due to ARDS. In patients with severe, 
resistant hypoxia, veno -venous extracorpore-
al membrane oxygenation (V-V ECMO) may be 
considered. The presence of an interatrial shunt 
may, in fact, be beneficial in V-V ECMO.5
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